What's on this Page
Diroximel Fumarate Brand Name
What is Diroximel Fumarate
Diroximel fumarate is an oral fumarate.
Like dimethyl fumarate, the drug is indicated for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Oral fumarates appear to have neuroprotective and anti-inflammatory properties; these actions can help delay disability and disease progression.
Diroximel fumarate has the same active metabolite (MMF) as dimethyl fumarate.
In clinical studies assessing safety in adult patients with relapsing-remitting multiple sclerosis (RRMS), approximately 700 patients were treated with diroximel fumarate and approximately 490 patients received more than 1 year of treatment with the drug.
The adverse reaction profile of diroximel fumarate was consistent with the experience in the placebo-controlled clinical trials with dimethyl fumarate.
Diroximel fumarate’s main advantage over dimethyl fumarate is better GI tolerability. Less patients discontinued treatment becuase of GI adverse effects with diroximel fumarate (0.8%) than dimethyl fumarate (4.8%).
Diroximel fumarate was FDA approved in October 2019
Indications
- multiple sclerosis
For the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Side Effects
- abdominal pain
- anaphylactoid reactions
- angioedema
- diarrhea
- dyspepsia
- elevated hepatic enzymes
- eosinophilia
- erythema
- flushing
- infection
- leukoencephalopathy
- leukopenia
- lymphopenia
- lymphopenia
- nausea
- progressive multifocal leukoencephalopathy
- proteinuria
- pruritus
- rash
- urticaria
- vomiting
Monitoring Parameters
- CBC
- LFTs
- serum bilirubin
Contraindications
- breast-feeding
- hepatic disease
- hepatotoxicity
- immunosuppression
- pregnancy
- progressive multifocal leukoencephalopathy
- renal failure
- renal impairment
Interactions
- Dimethyl Fumarate
- Ethanol
- Ocrelizumab
- Ozanimod